Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 156,510 |
|
|||||
| News | - | ||||||
| Day High | 1.925 | Low High |
|||||
| Day Low | 1.84 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Checkpoint Therapeutics Inc | CKPT | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.02 | 1.06% | 1.91 | 23:00:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.89 | 1.84 | 1.925 | 1.90 | 1.89 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 962 | 156,510 | US$ 1.89 | US$ 296,013 | - | 1.30 - 3.62 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:50:35 | 10 | US$ 1.91 | USD |
Checkpoint Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 44.93M | 23.53M | - | 103k | -51.85M | -2.20 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Checkpoint Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/24/2024 | 20:01 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/24/2024 | 15:06 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
| 5/16/2024 | 18:34 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/14/2024 | 06:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/10/2024 | 15:16 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/10/2024 | 07:45 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/01/2024 | 19:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/05/2024 | 16:00 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities |
| 2/02/2024 | 19:15 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/02/2024 | 16:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/30/2024 | 16:10 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 1/30/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CKPT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.84 | 1.925 | 1.75 | 1.82 | 202,140 | 0.07 | 3.80% |
| 1 Month | 1.48 | 2.12 | 1.47 | 1.76 | 445,369 | 0.43 | 29.05% |
| 3 Months | 2.14 | 2.24 | 1.38 | 1.77 | 382,082 | -0.23 | -10.75% |
| 6 Months | 2.55 | 3.62 | 1.36 | 2.08 | 664,646 | -0.64 | -25.10% |
| 1 Year | 2.65 | 3.62 | 1.30 | 2.12 | 470,688 | -0.74 | -27.92% |
| 3 Years | 27.00 | 46.40 | 1.30 | 17.55 | 630,158 | -25.09 | -92.93% |
| 5 Years | 41.70 | 53.762 | 1.30 | 21.87 | 614,341 | -39.79 | -95.42% |
Checkpoint Therapeutics Description
| Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). |
